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Summary 
In human and experimental  models of  arthritis, blood monocytes migrate into the inflamed synovium 
and joint space. The mechanisms required for monocyte  migration across the vascular endothelium 
in joints is poorly defined. Radiolabeled rat blood monocytes were used to measure monocyte 
migration to the inflamed  joints of rats with adjuvant arthritis, and the role of monocyte adhesion 
molecules was analyzed. Monocyte accumulation in the inflamed joints was maximal 14-21 d 
after  immunization with  adjuvant,  when arthritis  had fully developed.  Blocking  mAbs  to 
lymphocyte function-associated antigen 1 (LFA-1), Mac-l, and very late activation antigen 4 
(VLA-4) were used to evaluate the role of these integrins  in the migration. Migration to the 
joints was not inhibited  by treatment of the animals with mAb to LFA-1, Mac-l, or VLA-4 
alone, and was partially (50%) inhibited in only the most arthritic joint, the talar joint, by the 
combination of mAb to LFA-1 plus Mac-1. In contrast,  this combination inhibited migration 
to dermal inflammation induced by C5a~ A~s, endotoxin, tumor necrosis factor c~, and poly- 
inosine-cytosine by 60-70%. When mAbs to LFA-1 and VLA-4 were combined, migration to 
all the inflamed joints was strongly inhibited (80-98%, depending on the  joint). Treatment with 
the combination of the three mAbs to LFA-1, Mac-l, and VLA-4 completely eliminated mono- 
cyte migration to all joints and dermal inflammation. The results show that 51Cr blood mono- 
cytes can be used to quantify monocyte migration to arthritic joints in the rat.  LFA-1 alone 
or VLA-4 alone is sufficient to mediate most of this migration, and either LFA-1 or VLA-4 
is required for monocyte migration to joint inflammation.  These results indicate that both the 
VLA-4 and LFA-1 integrins should be therapeutic targets for suppression of monocyte infiltration 
of joints in arthritis. 
I 
nflammation is characterized by PMN and mononuclear 
cell margination in the microvascular bed and the migra- 
tion of these leukocytes into the extravascular  space. This pro- 
cess is in part initiated by chemotactic  factors, which directly 
stimulate adhesion and migration of leukocytes via leukocyte 
receptors (1-3).  A number of cytokines, in particular  IL-1 
and  TNF-ol,  have been  shown  to  stimulate  vascular en- 
dothelium to express adhesion molecules, which interact with 
counterreceptors on leukocytes including monocytes, resulting 
in their adhesion and transendothelial migration (4-6).  The 
accumulation  of blood monocytes in sites of inflammation 
is a common feature in many inflammatory conditions,  in- 
cluding human rheumatoid arthritis,  and in experimental 
models of arthritis  (7-9). These cells differentiate into mac" 
rophages in the tissues and are believed to contribute to the 
inflammatory reaction through their capacity to present an- 
tigen and secrete cytokines, growth factors, oxygen radicals, 
and proteolytic and degradative enzymes (10-12). Therefore, 
the factors involved in recruiting monocytes from the blood 
into the tissues and the actual mechanisms used by these cells 
for migrating across the vascular wall are important to un- 
derstand if one is to develop strategies for modulating chronic 
inflammation. 
The B2 integrin family of leukocyte membrane glycopro- 
teins also known as CDll/CD18, are recognized as impor- 
tant surface molecules for the adhesion of all types of leuko- 
cytes to vascular endothelium and extracellular matrix (4, 5, 
13). Monocytes express all three forms of the CD11/CD18 
complex,  namely LFA-1 (CDlla/CD18),  Mac-1 (CDllb/ 
CD18), and p150/95 (CDllc/CD18) (13). Each of these share 
the common/~2 integrin chain (CD18) but have different c~ 
chains (CD11a, CD11b, or CD11c), which form o~B hetero- 
dimers with some unique and some overlapping functions 
(13, 14). CDll/CD18 glycoproteins are recognized as essen- 
tial for PMN migration, as illustrated by patients who have 
leukocyte adhesion deficiency (LAD) disease, a condition in 
which synthesis of the B chains is abnormal or completely 
deficient, resulting in virtual absence  of the CDll/CD18 tool- 
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pairment in the mobilization of leukocytes, especially PMN, 
from blood into sites of infection. Investigation of leukocyte 
adhesion deficiency disease patients, plus in vitro and in vivo 
studies using mAb to block the CD11/CD18 adhesion mol- 
ecules, have demonstrated a nearly absolute requirement for 
this adhesion glycoprotein complex in mediating the migra- 
tion of PMN in vivo and across vascular endothelium in vitro 
(4, 15-19). However, the mechanisms used by monocytes for 
migration appear  to be somewhat more complex. Recent 
studies by ourselves and others indicate that monocytes may 
also utilize the ot4/~1 integrin, also known as very late acti- 
vation antigen 4 (VLA-4),  1 for migration across vascular en- 
dothelium in vitro (20, 21) and to peritoneal inflammatory 
reactions in vivo (22). 
We have recently developed techniques in the rat for quan- 
titating blood monocyte migration to sites of inflammation 
in the skin, induced by chemotactic factors and inflamma- 
tory cytokines (23). Here, we have investigated the migra- 
tion of rat blood monocytes to inflamed joints of rats with 
adjuvant arthritis, which is one model of human arthritis. 
Using  this  model, we have used mAb  to subunits  of the 
CDll/CD18 complex, i.e.,  to LFA-1 and Mac-l, and mAb 
to VLA-4 to define the role of these adhesion molecules on 
monocyte  migration to chronic  joint inflammation. Our results 
indicate that monocytes migrate actively into the inflamed 
joints of rats with arthritis at the height of clinical inflam- 
mation. This migration is mediated by both the CD11/CD18 
adhesion molecules, in particular LFA-1, and by VLA-4. Since 
monocyte  migration  to  arthritis  is  completely inhibited 
(>98%) when both of these adhesion molecule complexes 
are blocked, monocyte infiltration to inflamed joints appears 
to absolutely require these mechanisms. 
Materials  and Methods 
Animals.  Adjuvant  arthritis was induced in 6-8-wk-old inbred 
male Lewis strain rats by immunization  on the lower back with 
0.5 mg Mycobacterium butyricum (Difco Laboratories, Inc., Detroit, 
MI) in 0.05 ml mineral oil in two sites subcutaneously at the base 
of the tail. All the animals developed  polyarticular arthritis between 
days 11 and 13 after immunization. For clinical scoring, 0-4 points 
were assigned per limb and tail, based on the severity of erythema, 
swelling, and limitation of movement. The maximum possible score 
was 20 (9). 
Monocyte Isolation and Labeling.  Rat blood monocytes for migra- 
tion studies were obtained using the hydroxyethyl starch exchange 
transfusion technique of Williams et al. (24) as modified by us pre- 
viously for blood monocyte migration studies (23). Briefly,  the total 
blood volume of a donor rat was exchanged  using 50 ml 6% hydrox- 
yethyl-starcb-saline  (DuPont Chemical Co., Dorval, Canada). After 
recovery of 45-50 ml blood hydroxyethyl starch perfusate, the red 
cells were allowed to sediment and the leukocyte rich plasma was 
harvested.  The  leukocytes  were  recovered by  centrifugation, 
1 Abbreviations used in this  paper: poly hC, polyinosine-cytosine;  Tyr-10% 
PPP, Tyrode's  solution  plus 10% platelet  poor plasma; VCAM-1, vascular 
cell adhesion molecule 1; VLA-4, very  late activation antigen 4; ZAS, 
Zymosan-activated  serum. 
resuspended in calcium-magnesium-free  Tyrode's  solution plus 10% 
platelet-poor plasma (Tyr-10% PPP), and layered onto 63% iso- 
tonic Percoll (Pharmacia Fine Chemicals, Dorval, Canada) layered 
above 74% Percoll. After centrifugation,  the mononuclear layer 
on the top of the 63% Percoll was removed, washed, and resus- 
pended in Tyr-10% PPP. The osmolality was slightly increased by 
the addition of 9% NaC1 to improve the separation of monocytes 
from lymphocytes as reported previously (23). The cell suspension 
was layered onto a 40%/55%/58% Percoll gradient.  After cen- 
trifugation,  monocytes were harvested at  the 40/55%  and the 
55/58% interphases. The purified monocytes were washed and la- 
beled with 75/~Ci Na2SlCrO4 (Amersham, OakviUe, Canada) in 
1 ml Tyr-10% PPP at 37~  for 30 mins. Monocytes were then 
washed and 4-6  x  106 monocytes, carrying 1-1.5  x  l0  s cpm StCr 
were injected intravenously into each rat. The injected cells con- 
tained minimal platdets and were >85%, and usually >90% mono- 
cytes as reported previously (23). The viability of labeled cells was 
confirmed by: (A) >95% Trypan blue dye exclusion and staining 
with the vital dye, neutral red; (B) very active accumulation of la- 
baled cells in dermal inflammatory reactions; and (C) retention of 
>95% SlCr on the labeled monocytes in the circulation 2 h after 
intravenous injection of the cells as reported previously (23). The 
purified, labeled monocytes also showed no significant (<6%) in- 
crease in Mac-1 expression measured by immunofluorescence flow 
cytometry compared to monocytes in blood. 
Monoclonal Antibodies and Antibody Treatment.  The mAb MRC 
OX-42 was a kind gift from Dr. D.W. Mason (University of Ox- 
ford, Oxford, United Kingdom), It is a mouse IgGh mAb which 
reacts with the c~ chain of rat Mac-1 (CDllb/CD18; CR3) and 
blocks its adhesive functions as shown previously (18). It was used 
as the F(ab)2 fragment generated by pepsin digestion using stan- 
dard techniques. The TA-3 mAb is an IgGl mAb produced in our 
laboratory. It reacts with the c~ chain of rat LFA-1 and blocks its 
function (18, 25). The TA-2 mAb is an IgGl mAb described pre- 
viously (26). It reacts with cz4 and blocks in vitro adhesion and 
in vivo lymphocyte migration  mediated by VLA-4 (26-28). 
Control mAbs included 1G8 and 2CB4E1, which were gener- 
ated in our laboratory and react with rat monocytes to approxi- 
mately the same cell surface density as a saturating concentration 
of OX-42 and TA-3, as determined by flow cytometry. Antibody 
1G8 (IgG3) immunoprecipitates 160, 45, and 30 kD polypeptides, 
and  2CB4E1 (IgGh)  immunoprecipitates  a 65  kD  polypeptide 
from rat leukocytes. Additionally, mAb B9 (IgG~), which reacts 
with pertussis toxin and is, thus, an irrelevant, nonbinding  anti- 
body, was also employed as reported previously (18, 29). All of the 
mAbs were grown in ascites in mice, and ammonium sulfate-precipi- 
tated IgG was used. 
The effect of the mAbs on monocyte migration in vivo was as- 
sessed by giving animals an intravenous injection of 1-2 mg TA-2, 
or TA-3 IgG, or the F(ab2) fragment of OX-42 immediately be- 
fore intravenous injection of labeled monocytes. None of the mAb 
treatments caused neutropenia, lymphopenia, or clearance of the 
SlCr monocytes from the circulation, when compared to animals 
not receiving any antibodies. 
Dermal Inflammatory Reactions.  Inflammatory reactions, which 
we have previously shown to induce monocyte accumulation (23), 
were induced in the rats by intradermal (id) injection. Recombinant 
mouse TNFcr was a gift from Genentech Inc. (South San Fran- 
cisco, CA). Poly-I:C  was from Sigma  Chemical Co. (St. Louis, MO), 
and Escherichia coli 0111 endotoxin (LPS) was from List Biological 
Laboratories, Inc. (Campbell, CA). Zymosan-activated  serum (ZAS) 
generated by activating complement in normal rat serum with 
zymosan A (Sigma Chemical Co.) and followed by removal of the 
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factor C5a~ ^~g (30). 
Measurement of  Monocyte Migration.  Rats were anesthetized and 
injected intravenously with SlCr-labeled  monocytes. Immediately 
afterward, the skin on the back of the animals was shaved and the 
inflammatory stimuli injected intradermally into two sites. 2 h hter, 
blood was collected to measure blood S~Cr, and the animals were 
killed.  The dorsal skin, including the area of dermal inflammatory 
reactions, was removed and frozen, and the injected skin sites were 
punched out with a 12-ram punch and counted in a gamma spec- 
trometer (1280; LKB Instruments, Inc., Gaithersburg, MD). The 
forelimbs were  sectioned,  leaving the  forepaws  (containing  the 
metacarpal and phalangeal joints) and the carpal joints as separate 
samples for gamma counting.  Similarly,  the hindlimbs were sec- 
tioned just above and below the tibiotalarjoint, providing hindpaws 
(containing metatarsal phalangeal and phalangeal joints) and talar 
joint  samples for gamma counting.  The 51Cr content  of all  the 
tissues  is expressed as S~Cr cpm per  106 cpm injected. 
Statistical Methods.  Statistical  significance was determined using 
the Student's  t  test. 
Resuks 
Monocyte Migration to Joints  of Animals with Arthritis.  In 
initial  experiments,  the  migration  of  SlCr-labeled  blood 
monocytes to joints was measured at various times after im- 
munization  with M.  butyricum to induce  adjuvant  arthritis 
(Fig. 1). The monocyte accumulation was determined during 
a  2-h period  at each time point.  Thus,  the results  indicate 
the rate of migration at different stages after immunization. 
There  was  no  increase  in  the  migration  of  SlCr-labeled 
monocytes in the first week after immunization, but, between 
7  and  14  d,  there was  a  marked  increase,  most  notably  in 
the talarjoint, which in this model is the most severely affected 
joint.  Polyarticular arthritis was present in all of the animals 
immunized  and developed on day 10 or 11 after immuniza- 
tion.  The clinical  score of animals  at  14 d  was  11.8  _  0.4 
and, at 21 d,  13.6  +  1.0. Fig.  1 shows that monocyte migra- 
tion to the talar joints decreased by 21 d but remained high 
in  the hind  paws,  carpal joints,  and  tail,  which  is  affected 
by spondylitis  in  this  model. 
Effect of mAb to LFA-I  and Mac-I  on Monocyte Migration 
to Arthritic Joints.  To evaluate the role of LFA-1 and Mac-1 
on monocytes in mediating migration into inflamed joints, 
animals were treated 14-16 d after immunization when mono- 
cyte migration to all the joints was at or near its maximum. 
Animals received an intravenous injection of mAb OX42 to 
Mac-l, mAb TA-3 to LFA-1, or a combination of both mAbs 
or control mAbs,  and,  immediately afterward,  an injection 
of 51Cr-hbeled monocytes. The animals were then killed 2  h 
later.  As  shown  in  Fig.  2,  monocyte  accumulation  in  the 
lesions was not affected by the control mAb treatment, namely 
the  migration  was comparable  to  that  in  which  no  mAbs 
were used (Fig. 1). Treatment with mAb to Mac-1 or to LFA-1 
had no significant inhibitory effect on monocyte accumula- 
tion in any of the joints  or in the tail.  The combination  of 
antibody  to  Mac-1  and  to  LFA-1  inhibited  only  the  most 
severe  joint involved, namely the talar joint, and, here, mono- 
cyte accumulation  was  suppressed by only  50%. 
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Figure  1.  The kinetics ofmonocyte migration to joints after induction 
of adjuvant arthritis. Rats were immunized with M. t~tl~um and, at var- 
ious times thereafter, as indicated, monocyte migration to the inflamed 
joints was quantified. For this, SlCr-labeled  blood monocytes  were injected 
intravenously, and the animals  were killed  2 h later. Monocyte  accumuhtion 
is expressed  as the cpm accumulated in the tissue during the 2 h-period. 
Values are mean  +  SEM of 8-15 animals in each group. *P <0.001. 
Effect of mAb to VLA-4 and to LFA-I and Mac-1 on Mono- 
cyte Migration  to Joints.  In  addition  to  LFA-1  and  Mac-l, 
monocytes  also express  the  cr  integrin,  VLA-4,  which, 
in vitro,  can mediate monocyte adhesion  (4,  6,  13,  31,  32). 
Figure 2.  The effect of treatment with mAb to Mac-I and LFA-1 on 
monocyte migration to arthritic joints. Rats with severe  arthritis at day 
14 to 16 after immunization were injected intravenously  with control mAb 
(2CB4E1, Bg, or 1G8), anti-Mac-1 (mAb MRC OX-42), anti-LFA-1 (mAb 
TA-3), or a combination of both these antibodies as indicated. Immedi- 
ately thereafter, the animals were injected with slCr-labeled  blood mono- 
cytes. 2 h later, the rats were killed and slCr monocyte accumulation was 
determined as in Fig. 1. Values are mean _+ SEM of 5-15 animals in each 
group. Values for background monocyte accumulation in corresponding 
joints  of normal nonarthritic  animals were subtracted from each value. 
These corresponded to 1,311 cpm in talar  joint, 1,201 cpm in the hindpaw, 
648 cpm in the carpal joint,  and 1,715 cpm in the tail. *P <0.05. Therefore, the effect of blocking the r  chain of VLA-4 on 
in vivo monocyte  migration to joints at 14-16 d after immu- 
nization was investigated. As Fig. 3 shows, treatment with 
anti-VLA-4 had no significant inhibitory effect on monocyte 
accumulation  in the talar joint, carpal joint, or tail, but it 
inhibited, by "~60%, monocyte accumulation in the hindpaw 
(i.e., in the small joints of the foot). When anti-VLA-4 was 
combined with anti-Mac-I, there was some inhibition of 
monocyte accumulation in the  joints, which reached statisti- 
caUy  significant  levels only in the talar joint. In contrast, when 
anti-VLA-4 was combined with anti-LFA-1, monocyte migra- 
tion was much more profoundly inhibited.  This combina- 
tion resulted in at least 80% inhibition of monocyte accumu- 
lation in the talarjoint, hindpaw, and tail, and nearly complete 
inhibition of  monocyte accumulation (i.e., 98%) in the carpal 
joint. Experiments were also performed with a combination 
of all three mAbs to block VLA-4, Mac-l, and LFA-1. Es- 
sentially, this combination of  mAbs completely  blocked mono- 
cyte migration to all of the inflamed  joints. Furthermore, the 
combination of the three mAbs completely  inhibited mono- 
cyte migration to joints of animals 21 d after immunization 
(not shown). 
Effect of mAb to Mac-I, LFA-1, and VLA-4 on Monocyte Migra- 
tion to Dermal Inflammation.  The migration of monocytes 
to dermal inflammatory reactions was also evaluated in the 
same animals which were used for the arthritis  studies in 
Figs. 2 and 3. Inflammation in the skin was induced by in- 
tradermal injection of ZAS (as a source of CSaa~s ^r~ [30]), 
H~re  3.  The effect of treatment with antibody to VLA-4 and to Mac-l, 
or LFA-1 on monocyte migration to arthritic  joints. Animals with severe 
arthritis as in Fig.  2 were injected intravenously with anti-VLA-4 (mAb 
TA-2),  or anti-VLA-4  +  anti-Mac-1 (TA-2  +  OX-42),  or anti-VLA-4 
+  anti-LFA-1 (TA-2 +  TA-3) mAbs, or a combination of all three mAbs, 
as indicated before intravenous injection of slCr-labeled blood monocytes. 
Monocyte accumulation in the joints was measured after 2 h and is ex- 
pressed as in Figs.  1 and 2. Values are mean  _+  SEM of 5-15 animals in 
each group, and values for normal, noninflamed joints were subtracted 
as in Fig.  2.  *P <0.05;  **P <0.01;  ***P <0.001. 
LPS, TNFol, and the interferon inducer, polyinosine-cytosine 
(poly I:C). Each of these stimuli induced marked monocyte 
accumulation in the cutaneous lesions, which was not affected 
by treatment with control mAbs (Fig. 4). Treatment of rats 
with the mAb to Mac-1 in combination with mAb to LFA-1 
inhibited  60-75%  monocyte accumulation  to each of the 
stimuli. In contrast, treatment with mAb to VLA-4 had no 
affect on monocyte accumulation to any of the four inflam- 
matory stimuli. However, when the antibodies to Mac-1 and 
LFA-1 were combined with the mAb to VLA-4, monocyte 
accumulation in the dermal inflammatory  reactions was vir- 
tually completely inhibited (>98%), as was the case in the 
arthritis joints. 
Discussion 
In the experiments reported here, we have shown that a 
recently developed  technique, using radiolabeled  blood mono- 
cytes harvested from rats, can be used to quantitate mono- 
cyte migration and accumulation  in the joints of rats with 
adjuvant arthritis.  This accumulation increased during, and 
roughly correlated with the clinical signs of, joint inflamma- 
tion (Fig. 1). Interestingly, the results also suggest that LFA-1 
and Mac-1  (CD11/CD18)  are not  required  for monocyte 
migration to the inflamed joints (Fig. 2). Migration to the 
smaller  joints (carpal, hindpaw, and tail) was not significantly 
affected by treatment with mAbs to LFA-1 and Mac-l, and 
was only partially inhibited to the talar joint. This contrasts 
with the 60-75%  inhibition by the mAb combination of 
monocyte  migration to dermal inflammation induced by four 
different stimuli (ZAS, LPS, TNFa,  and poly I:C) in the 
same animals (Fig. 4). The cutaneous results demonstrate that 
the mAbs to Mac-1 and LFA-1 were able to block migration 
in the arthritic animals. This is also in accordance  with previous 
investigations in this model in which the mAbs,  used here 
to Mac-1 and LFA-1, blocked 90-95% of PMN accumula- 
tion in acute dermal inflammatory reactions and inhibited 
PMN accumulation in inflamed joints by 50% (18, 29). The 
mAbs used here have also been shown, in vitro, to block PMN 
and  lymphocyte adhesion  to  rat  vascular endothelium, 
confirming that they recognize epitopes involved in adhesion 
functions  (18, 25,  26).  Furthermore, in  the  presence of 
anti-VLA-4, anti-Mac-I,  and anti-LFA-1, monocyte accumu- 
lation in the skin was completely inhibited,  suggesting that 
Mac-1 and LFA-1 were completely blocked by these mAb 
treatments. The conclusions which can be drawn from these 
findings are that blood monocytes, in migration to chroni- 
cally inflamed joints, use mechanisms distinct  from LFA-1 
and Mac-1 and, in fact, distinct from all CD11/CD18  family 
members, because,  in recent experiments, identical results were 
obtained with an anti-CD18 mAb (WT-3, kindly provided 
by Dr. M. Miyasaka) that blocks all members of the CDll/ 
CD18  complex (33). 
Lymphocytes, eosinophils, and monocytes also express the 
fll integrin, VLA-4 (a4fl0, which is involved in adhesion, 
especially to cytokine-activated endothelium, by binding to 
vascular cell adhesion molecule-1 (VCAM-1)  on the endothelial 
cell (4-6, 13, 32, 34). The TA-2 mAb reacts with o~4 of rat 
1200  Mono~te Migration to Arthritis Figure 4.  The effect  of  antibody  to VLA-4,  and to Mac-1 
and LFA-1, on monocyte  migration to dermal inflamma- 
tion. In the animals  in Figs. 2 and 3, immediately  after  in- 
travenous  injection  of the mAbs, slCr-labeled  blood  mono- 
cytes were  injected  intravenously  and dermal  inflammatory 
reactions  were  induced  by intradermal  injection  of  50% ZAS, 
1 ng of endotoxin  (LPS), 10 ng mouse  TNF-cx, or 100 ng 
poly  I:C per site. The labeled  cells  were  allowed  to accumu- 
late in the skin sites for 2 h. At the same time they were 
also migrating  to the inflamed  joints. Values in control 
diluent-injected  sites averaged  75 cpm and were subtracted 
from  all the values. Values  are mean _+ SEM of  5-15 animals 
in each  group. *P <0.001; **P <0.00I, relative  to anti-Mac-I 
and anti-LFA-1. 
Ot4B1 (VLA-4),  blocks its adhesion function, and inhibits the 
migration  of  T  lymphocytes to  inflammatory reactions 
(26-28). TA-2 also binds to VLA-4 on rat blood monocytes. 
Blocking VLA-4 caused only a mild, and in most joints, a 
statistically insignificant effect on monocyte accumulation. 
This treatment also had no effect on monocyte migration 
to the dermal inflammatory reactions. These findings sug- 
gest that, by itself, VLA-4 plays a minor role in monocyte 
migration to inflammation in these arthritic animals.  How- 
ever, the importance of VLA-4 in this migration became ap- 
parent when it was found that blocking VLA-4 in animals 
treated with anti-LFA-1 and anti-Mac-1 mAbs completely 
eliminated monocyte migration to the joints and to dermal 
inflammation. This suggests that VLA-4 can function as an 
alternate adhesion/migration molecule to the CD11/CD18 
complex in mediating monocyte migration. In acute inflam- 
mation in skin, the CD11/CD18  complex appears  to play 
a significant role by itself in monocyte accumulation, but in 
the chronic inflammation associated with arthritis, the bal- 
ance between VLA-4 and CD11/CD18 (LFA-1 and Mac-l) 
usage is such that either VLA-4 or CD18 integrins can mediate 
near-maximal monocyte accumulation. These conclusions are 
in agreement with a recent report by Winn and Harlan (22), 
showing that mononuclear cell  accumulation in inflamed 
peritoneum in rabbits  was not inhibited by mAb to CD18 
or to VLA-4 treatment alone,  but  was almost completely 
blocked by a combination of these two antibodies. 
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The findings reported here are unique in that they are, to 
our knowledge, the first demonstration of the kinetics of ra- 
diolabeled blood monocyte migration to joints of rats with 
adjuvant arthritis, the first to demonstrate that both CDll/ 
CD18 and VLA-4 are involved in this migration process, and 
the first to use CD11  subunit specific antibodies (i.e., to the 
CDlla subunit of LFA-1 and the CDllb subunit of Mac-l) 
to dissect the relative contribution of each of these integrins 
to monocyte migration.  The contributions of LFA-1  and 
Mac-1 were only apparent when the VLA-4 adhesion/migra- 
tion mechanism was blocked. As shown in Fig. 3, addition 
of anti-LFA-1 to anti-VLA-4 inhibited monocyte migration 
almost completely to the carpal joint and by 80% to the other 
joints. These observations suggest that Mac-1 plays a lesser 
role than LFA-1 in monocyte migration to arthritis. Similar 
conclusions were reached in a previous study regarding PMN 
migration to joint inflammation, which showed that anti- 
LFA-1 mAb inhibited as well as a combination of anti-LFA-1 
plus anti-Mac-1 mAbs did, despite the fact that, for com- 
plete inhibition of migration to dermal inflammation, both 
LFA-1 and Mac-1  on the PMN had to be blocked (18, 29). 
The findings here also suggest that, in chronic  joint inflam- 
mation, the relative contribution ofVLA-4, LFA-1, and Mac-1 
to monocyte migration are different from that observed with 
acute dermal inflammation. The increased  VLA-4 usage in 
monocyte migration to chronic arthritic joints may be ex- 
plained, in part, by our recent in vitro studies, in which mono- cyte migration across unstimulated vascular endothelium (in 
response  to CSa chemotactic factor) was largely dependent 
on CD11/CD18. Anti-CD18 inhibited 70-75% of the migra- 
tion and monocytes from a patient with CD18 deficiency who 
had a similar impairment of monocyte transendothelial migra- 
tion. However, activation of the endothelium with cytokines 
such as IL-1, TNF-c,, or LPS resulted in monocyte migration 
to CSa, which was CD11/CD18-independent and was medi- 
ated by VLA-4 on the monocyte interacting with VCAM-1 
on activated  endothelium (20).  These conditions are likely 
to be operative during chronic joint inflammation in arthritis, 
since vascular endothelium in rheumatoid synovium expresses 
the adhesion molecules E-selectin, intercellular adhesion mol- 
ecule  1 (ICAM-1), and VCAM-1,  and synovial fluid from 
such joints contain chemotactic factors for monocytes, such 
as C5a, monocyte chemotactic protein (MCP)-I, and LTB-4 
(2,  12,  35-38).  In addition, the alternatively spliced CS-1 
fragment of fibronectin may also act as a ligand for VLA-4 
and contribute to this migration (31, 39). The inflammatory 
reactions induced in the skin lasted only 2 h and may have 
been too short for adequate expression  of VCAM-1 on en- 
dothelium for optimal VLA-4-mediated migration. Later time 
points were not studied. Nevertheless,  even at 2 h  a small 
VLA-4 component of the monocyte migration appeared to 
be present in acute dermal reactions when both LFA-1 and 
Mac-1  were blocked. 
In conclusion, these results demonstrate that monocyte 
migration to both acute dermal inflammatory reactions and 
to arthritis involves both the CDll/CD18 (LFA-1 and Mac-l) 
and the VLA-4 adhesion molecules, and that, in chronic  joint 
inflammation, either mechanism can be alternatively used to 
maintain normal or near normal monocyte migration. These 
conclusions may apply to monocyte  infiltration in other chronic 
inflammatory conditions as well. 
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